Table 4.
Cerebrovascular and cardiorespiratory variables during hypercapnia.
| Placebo | Indo | |||
|---|---|---|---|---|
| Men | Women | Men | Women | |
| MABP (mmHG) | ||||
| Baseline | 90 ± 1 | 87 ± 1 | 95 ± 2 | 91 ± 2 |
| Hypercapnia | 92 ± 1 | 89 ± 2 | 96 ± 2 | 94 ± 2 |
| HR (beats min−1) | ||||
| Baseline | 65 ± 6 | 69 ± 2 | 62 ± 6 | 63 ± 2 |
| Hypercapnia | 65 ± 5 | 64 ± 3 | 61 ± 6 | 62 ± 2 |
| PETCO2 (mmHG)1,2,4 | ||||
| Baseline | 39 ± 1 | 38 ± 0 | 38 ± 1 | 37 ± 0 |
| Hypercapnia | 49 ± 1 | 47 ± 0 | 48 ± 1 | 47 ± 0 |
| SPO2 (%)24 | ||||
| Baseline | 99 ± 0 | 99 ± 0 | 99 ± 0 | 99 ± 0 |
| Hypercapnia | 100 ± 0 | 100 ± 0 | 100 ± 0 | 100 ± 0 |
| MCAv (cm sec−1)1,2,3,4 | ||||
| Baseline | 72 ± 3 | 79 ± 3 | 48 ± 2 | 55 ± 2 |
| Hypercapnia | 91 ± 4 | 101 ± 4 | 55 ± 3 | 64 ± 3 |
| ΔMCAv | ||||
| Hypercapnia | 19 ± 1 | 23 ± 2 | 8 ± 1 | 9 ± 1 |
| %ΔMCAv | ||||
| Hypercapnia | 27 ± 2 | 30 ± 2 | 16 ± 2 | 17 ± 2 |
| CVCi (cm sec−1 mmHG−1)1,2,3,4 | ||||
| Baseline | 80 ± 3 | 90 ± 4 | 50 ± 2 | 60 ± 2 |
| Hypercapnia | 100 ± 4 | 114 ± 4 | 58 ± 3 | 69 ± 3 |
| Δ CVCi | ||||
| Hypercapnia | 20 ± 2 | 23 ± 2 | 8 ± 1 | 9 ± 1 |
| %Δ CVCi | ||||
| Hypercapnia | 25 ± 2 | 27 ± 2 | 15 ± 2 | 14 ± 2 |
Values are means ± SE. Indo, indomethacin; MABP, mean arterial blood pressure; HR, heart rate; PETCO2, end-tidal carbon dioxide; SPO2, pulse oximetry oxygen saturation; MCAv, middle cerebral artery velocity; ΔMCAV, change in MCAv from baseline; %ΔMCAV, percent change in MCAv from baseline; CVCi, cerebrovascular conductance index; ΔCVCi, change in CVCi from baseline; %ΔCVCi, percent change in CVCi from baseline.
1
Placebo, main effect of group.
2
Placebo, main effect of hypercapnia.
3
Indo, main effect of group.
4
Indo, main effect of hypercapnia; P < 0.05.